Shattuck Labs (NASDAQ:STTK - Get Free Report) was upgraded by stock analysts at Leerink Partnrs to a "strong-buy" rating in a note issued to investors on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for Shattuck Labs' Q4 2024 earnings at ($0.30) EPS, FY2024 earnings at ($1.42) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.93) EPS and FY2026 earnings at ($0.93) EPS.
Separately, Leerink Partners began coverage on Shattuck Labs in a report on Monday, March 17th. They issued an "outperform" rating and a $4.00 target price on the stock. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Shattuck Labs has an average rating of "Moderate Buy" and an average target price of $7.50.
Check Out Our Latest Stock Report on Shattuck Labs
Shattuck Labs Stock Up 3.4 %
Shares of NASDAQ STTK traded up $0.04 during trading on Monday, reaching $1.20. 186,977 shares of the stock were exchanged, compared to its average volume of 380,108. The business's 50-day moving average price is $1.24 and its 200 day moving average price is $1.56. Shattuck Labs has a twelve month low of $0.94 and a twelve month high of $11.76. The company has a market capitalization of $57.29 million, a price-to-earnings ratio of -0.78 and a beta of 1.66.
Institutional Trading of Shattuck Labs
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new stake in Shattuck Labs during the 3rd quarter worth approximately $121,000. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Shattuck Labs by 44.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 178,228 shares of the company's stock valued at $622,000 after acquiring an additional 54,505 shares during the period. FMR LLC boosted its position in Shattuck Labs by 0.4% during the third quarter. FMR LLC now owns 7,159,090 shares of the company's stock worth $24,985,000 after purchasing an additional 26,460 shares during the period. MetLife Investment Management LLC boosted its stake in Shattuck Labs by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company's stock valued at $86,000 after purchasing an additional 13,859 shares during the period. Finally, Atom Investors LP bought a new stake in Shattuck Labs in the 3rd quarter valued at $35,000. 58.74% of the stock is owned by institutional investors.
Shattuck Labs Company Profile
(
Get Free Report)
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Featured Articles
Before you consider Shattuck Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shattuck Labs wasn't on the list.
While Shattuck Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
